24 Week Open Label, Single Arm Study of Colesevelam in High Risk South Asians With Suboptimal LDL-c Levels Despite Maximally Tolerated Statin Therapy

Trial Profile

24 Week Open Label, Single Arm Study of Colesevelam in High Risk South Asians With Suboptimal LDL-c Levels Despite Maximally Tolerated Statin Therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Colesevelam (Primary)
  • Indications Coronary artery disease; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CLASS-ACT
  • Most Recent Events

    • 21 Jun 2016 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 21 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
    • 23 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top